Vor Biopharma Inc. Overview
Pro stress-test →Vor Biopharma is a clinical-stage cell and genome engineering company developing the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. The company aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
Strategic Profile
Pro stress-test →Vor has license agreements with Columbia University, the National Institutes of Health, and Editas Medicine for ex-vivo Cas9 gene-edited hematopoietic stem cell therapies. The company recently announced a strategic shift, winding down operations and exploring options to maximize shareholder value.
Competitive Landscape
Pro stress-test →Vor competes in the cell therapy oncology space against companies including Adaptimmune Therapeutics, NexImmune, Oxford Biotherapeutics, and Cara Therapeutics. The market is characterized by early-stage development programs with significant clinical and commercial execution risk.
Industry Context
Vor Biopharma Inc. operates in Biopharmaceutical / Cell & Gene Therapy.
Key facts
Founded: 2015 · Headquarters: Cambridge, Massachusetts · Market cap: $191M